For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

CEO David Veitch | Half-year 2019 Update

Play

News

Aug 20. 2019
Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
Read more Download
Aug 13. 2019
Basilea starts phase 1/2 study with derazantinib in urothelial cancer
Read more Download
Aug 06. 2019
Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)
Read more Download
Jul 01. 2019
Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
Read more Download

 

News Archive

Half-year Report 2019

Download English
Download German

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures